JCDSA  Vol.3 No.1 A , January 2013
A Novel Vehicle Formulation for Treatment of Inflammatory Skin Diseases

Objective: To test the efficacy of a new topical vehicle formulation containing cetirizine in emu oil in treating inflammatory skin conditions. Methods: A single blind half body comparative study of patients with psoriasis, atopic and stasis dermatitis were all treated with midpotency topical steroid (desoximethasone) in propylene glycol base, desoximethasone and cetirizine in propylene glycol base, desoximethasone in emu oil base and desoximethasone with cetirizine dissolved in emu oil. Results: Based on patients’ ranking of creams’ efficacy, and supported by photographic data and investigators’ clinical assessment, results clearly indicated that desoximethasone and cetirizine in emu base was statistically more efficacious than either desoximethasone alone or with cetirizine in neutral propylene glycol base or desoximethasone in emu oil base (without cetirizine). Conclusions: Cetirizine and emu oil, having inherent anti-inflammatory and other beneficial properties synergistically, and by different biochemical pathways, enhance and magnify each other’s pharmaceutical effects that are useful in treatment of skin inflammatory diseases.

Cite this paper: A. Zemtsov and H. Hosier, "A Novel Vehicle Formulation for Treatment of Inflammatory Skin Diseases," Journal of Cosmetics, Dermatological Sciences and Applications, Vol. 3 No. 1, 2013, pp. 18-21. doi: 10.4236/jcdsa.2013.31A004.

[1]   S. Fireman, O. Toledano, K. Niemann, N. Loboda and N. Dayan, “A Look at Emerging Delivery Systems for Topical Drug Products,” Dermatologic Therapy, Vol. 24, No. 5, 2011, pp. 477-488. doi:10.1111/j.1529-8019.2012.01464.x

[2]   W. H. Eaglstein and G. Corcoran, “New Drugs and New Molecular Entities in Dermatology,” Archives of Dermatology, Vol. 147, No. 5, 2011, pp. 568-572. doi:10.1001/archdermatol.2011.100

[3]   L. H. Kircik, J. B. Bikowski, D. E. Cohen, Z. D. Draelos and A. Herbert, “Vehicles Matter; Formulation Development, Testing and Approval,” Practical Dermatology, Vol. 1, No. 1, 2010, pp. 3-16.

[4]   S. Farmer, “Emu Oil and Its Various Fractions as a Carrier for Antifungal, Antibacterial, and Antiviral Medications and Preparations,” US Patent 7048950, 2006.

[5]   J. M. Snowden and M. W. Whitehouse, “Antiinflammatory Activity of Emu Oil in Rats,” Inflammopharmacology, Vol. 5, No. 2, 1997, pp. 127-132. doi:10.1007/s10787-997-0021-x

[6]   X. W. Qui, J. H. Wang, X. W. Fang, Z. Y. Gong, Z. Q. Li and Z. H. Yi, “Anti-Inflammatory Activity and Healing-Promoting Effects of Topical Application of Emu Oil,” Academic Journal of the First Medical College of PLA, Vol. 25, No. 4, 2005, pp. 407-411.

[7]   A. Zemtsov, M. Gaddis and V. M. Montalvo-Lugo, “Moisturizing and Cosmetic Properties of Emu Oil: A Pilot Double Blind Study,” Australasian Journal of Dermatology, Vol. 37, No. 3, 1996, pp. 159-161. doi:10.1111/j.1440-0960.1996.tb01040.x

[8]   M. Boone, L. Lespagnard, N. Renard, M. Song and J. P. Rihoux, “Adhesion Molecule Profiles in Atopic Dermatitis vs. Allergic Contact Dermatitis:Pharmacologic Modulation by Cetirizine,” Journal of European Academy of Dermatology and Venereology, Vol. 14, No. 4, 2000, pp. 263-266. doi:10.1046/j.1468-3083.2000.00017.x

[9]   E. Pestelli, I. Florianati, P. Fabbri and M. Caproni, “Cetirizine Modulates Adhesion Molecule Expression in a Double-Blind Controlled Study in Psoriatic Patients,” International Journal of Tissue Reactions, Vol. 25, No. 1, 2003, pp. 1-8.

[10]   T. Jinquan, C. M. Reimert, B. Deleuran, C. Zachariae, C. Simonsen and K. Thestrup-Pederssen, “Ceterizine Inhibits the in Vitro and ex Vivo Chemotactic Response of T Lymphocytes and Monocytes,” Journal of Allergy and Clinical Immunology, Vol. 95, No. 5, 1995, pp. 979-986. doi:10.1016/S0091-6749(95)70098-6

[11]   M. Koller, R. A. Hilger, J. P. Rihoux and W. Konig, “Cetirizine Exerts Anti-Inflammatory Effects on Human Neutrophils,” International Archives of Allergy and Immunology, Vol. 110, No. 1, pp. 52-56.

[12]   A. Shobailli, “The Impact of Childhood Atopic Dermatitis on the Patient Family,” Pediatric Dermatology, Vol. 27, No. 6, pp. 618-623. doi:10.1111/j.1525-1470.2010.01215.x

[13]   B. A, Yentzer, R. A. Ade, J. M. Fountain, A. R. Clark, S. R. Taylor, E. Bonderding and S. R. Feldman, “Improvement in Treatment Adherence with a Three-Day Course of Fluocinonide Cream 0.1% for Atopic Dermatitis,” Cutis, Vol. 86, No. 4, pp. 208-213.

[14]   American Academy of Dermatology, “Psoriasis and Psoriatic Arthritis,” 2010.

[15]   J. W. Fluhr, C. Cavalotti and E. Benardesca, “Emollient Moisturizers and Keratolytic Agents in Psoriasis,” Clinics in Dermatology, Vol. 26, No. 4, 2008, pp. 380-386. doi:10.1016/j.clindermatol.2008.01.015